{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T14:18:09Z","timestamp":1768054689775,"version":"3.49.0"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T00:00:00Z","timestamp":1756598400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T00:00:00Z","timestamp":1756598400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["NWA.1160.18.038."],"award-info":[{"award-number":["NWA.1160.18.038."]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Appl Health Econ Health Policy"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s40258-025-00996-3","type":"journal-article","created":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T17:13:24Z","timestamp":1756660404000},"page":"111-129","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Systematic Review of Modelling Approaches in Economic Evaluations of Treatments for Inherited Bleeding Disorders"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-5289-0394","authenticated-orcid":false,"given":"Diaz M.","family":"Prameyllawati","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hester F.","family":"Lingsma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marjon H.","family":"Cnossen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renske M. T.","family":"Ten Ham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,31]]},"reference":[{"issue":"4","key":"996_CR1","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1542\/pir.29.4.121","volume":"29","author":"A Sharathkumar","year":"2008","unstructured":"Sharathkumar A, Pipe S. Bleeding disorders. Pediatr Rev. 2008;29(4):121\u201330.","journal-title":"Pediatr Rev"},{"issue":"21","key":"996_CR2","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1056\/NEJMra1601561","volume":"375","author":"FW Leebeek","year":"2016","unstructured":"Leebeek FW, Eikenboom JC. Von Willebrand\u2019s disease. N Engl J Med. 2016;375(21):2067\u201380.","journal-title":"N Engl J Med"},{"key":"996_CR3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1750-1172-1-10","volume":"1","author":"AT Nurden","year":"2006","unstructured":"Nurden AT. Glanzmann thrombasthenia. Orphanet J Rare Dis. 2006;1:10.","journal-title":"Orphanet J Rare Dis"},{"issue":"13","key":"996_CR4","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1182\/blood-2014-08-532820","volume":"125","author":"R Palla","year":"2015","unstructured":"Palla R, Peyvandi F, Shapiro AD. Rare bleeding disorders: diagnosis and treatment. Blood. 2015;125(13):2052\u201361.","journal-title":"Blood"},{"key":"996_CR5","doi-asserted-by":"publisher","first-page":"189","DOI":"10.2147\/JBM.S389241","volume":"14","author":"P Du","year":"2023","unstructured":"Du P, et al. Von Willebrand disease epidemiology, burden of illness and management: a systematic review. J Blood Med. 2023;14:189\u2013208.","journal-title":"J Blood Med."},{"issue":"S1","key":"996_CR6","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1097\/MBC.0000000000001222","volume":"34","author":"LQ Paris","year":"2023","unstructured":"Quintana Paris L. Foundations of hemophilia and epidemiology. Blood Coagul Fibrinolysis. 2023;34(S1):S35\u20136.","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"Suppl. 4","key":"996_CR7","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/hae.14524","volume":"28","author":"J Mahlangu","year":"2022","unstructured":"Mahlangu J, Iorio A, Kenet G. Emicizumab state-of-the-art update. Haemophilia. 2022;28(Suppl. 4):103\u201310.","journal-title":"Haemophilia"},{"issue":"1","key":"996_CR8","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1182\/hematology.2022000388","volume":"2022","author":"AC Nathwani","year":"2022","unstructured":"Nathwani AC. Gene therapy for hemophilia. Hematol Am Soc Hematol Educ Program. 2022;2022(1):569\u201378.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"3","key":"996_CR9","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jtha.2022.12.029","volume":"21","author":"PM Mannucci","year":"2023","unstructured":"Mannucci PM. Hemophilia treatment innovation: 50 years of progress and more to come. J Thromb Haemost. 2023;21(3):403\u201312.","journal-title":"J Thromb Haemost"},{"issue":"6","key":"996_CR10","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1080\/17474086.2023.2184341","volume":"16","author":"P Gogia","year":"2023","unstructured":"Gogia P, et al. New directions to develop therapies for people with hemophilia. Expert Rev Hematol. 2023;16(6):417\u201333.","journal-title":"Expert Rev Hematol"},{"key":"996_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2023.101164","volume":"64","author":"HAH Abdelgawad","year":"2024","unstructured":"Abdelgawad HAH, Foster R, Otto M. Nothing short of a revolution: novel extended half-life factor VIII replacement products and non-replacement agents reshape the treatment landscape in hemophilia A. Blood Rev. 2024;64: 101164.","journal-title":"Blood Rev"},{"issue":"1","key":"996_CR12","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13023-017-0660-y","volume":"12","author":"J O'Hara","year":"2017","unstructured":"O\u2019Hara J, et al. The cost of severe haemophilia in Europe: the CHESS study. Orphanet J Rare Dis. 2017;12(1):106.","journal-title":"Orphanet J Rare Dis"},{"key":"996_CR13","doi-asserted-by":"publisher","first-page":"107602962211205","DOI":"10.1177\/10760296221120583","volume":"28","author":"G Morgan","year":"2022","unstructured":"Morgan G, et al. The cost of Von Willebrand disease in Europe: the CVESS study. Clin Appl Thromb Hemost. 2022;28:10760296221120584.","journal-title":"Clin Appl Thromb Hemost"},{"issue":"3","key":"996_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12695","volume":"6","author":"MC Ozelo","year":"2022","unstructured":"Ozelo MC, Yamaguti-Hayakawa GG. Impact of novel hemophilia therapies around the world. Res Pract Thromb Haemost. 2022;6(3): e12695.","journal-title":"Res Pract Thromb Haemost"},{"issue":"6","key":"996_CR15","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.socscimed.2011.01.008","volume":"72","author":"A Brousselle","year":"2011","unstructured":"Brousselle A, Lessard C. Economic evaluation to inform health care decision-making: promise, pitfalls and a proposal for an alternative path. Soc Sci Med. 2011;72(6):832\u20139.","journal-title":"Soc Sci Med"},{"issue":"1","key":"996_CR16","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s40945-022-00154-1","volume":"12","author":"JH Abbott","year":"2022","unstructured":"Abbott JH, et al. Economic evaluation: a reader\u2019s guide to studies of cost-effectiveness. Arch Physiother. 2022;12(1):28.","journal-title":"Arch Physiother"},{"issue":"3","key":"996_CR17","first-page":"209","volume":"5","author":"F Xie","year":"2013","unstructured":"Xie F. Model-based economic evaluation for medical decision making: learn from the past and prepare for the future. J Thorac Dis. 2013;5(3):209\u201310.","journal-title":"J Thorac Dis"},{"issue":"2","key":"996_CR18","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1258\/135581904322987535","volume":"9","author":"P Barton","year":"2004","unstructured":"Barton P, Bryan S, Robinson S. Modelling in the economic evaluation of health care. J Health Serv Res Policy. 2004;9(2):110\u20138.","journal-title":"J Health Serv Res Policy"},{"issue":"2","key":"996_CR19","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000679","volume":"6","author":"RMT Ten Ham","year":"2022","unstructured":"Ten Ham RMT, et al. Modeling benefits, costs, and affordability of a novel gene therapy in hemophilia A. Hemasphere. 2022;6(2): e679.","journal-title":"Hemasphere"},{"issue":"5","key":"996_CR20","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1080\/13696998.2020.1721508","volume":"23","author":"K Cook","year":"2020","unstructured":"Cook K, et al. Assessing the potential cost-effectiveness of a gene therapy for the treatment of hemophilia A. J Med Econ. 2020;23(5):501\u201312.","journal-title":"J Med Econ"},{"issue":"3","key":"996_CR21","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s40273-017-0588-z","volume":"36","author":"PA Cortesi","year":"2018","unstructured":"Cortesi PA, et al. Modern treatments of haemophilia: review of cost-effectiveness analyses and future directions. Pharmacoeconomics. 2018;36(3):263\u201384.","journal-title":"Pharmacoeconomics"},{"key":"996_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71.","journal-title":"BMJ"},{"issue":"6","key":"996_CR23","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1080\/14737167.2016.1246961","volume":"16","author":"BFM Wijnen","year":"2016","unstructured":"Wijnen B, et al. How to prepare a systematic review of economic evaluations for informing evidence-based healthcare decisions: data extraction, risk of bias, and transferability (Part 3\/3). Expert Rev Pharmacoecon Outcomes Res. 2016;16(6):723\u201332.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"4","key":"996_CR24","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s41669-021-00283-6","volume":"5","author":"A Bullement","year":"2021","unstructured":"Bullement A, et al. Cost-effectiveness analysis of rFVIIIFc versus contemporary rFVIII treatments for patients with severe hemophilia A without inhibitors in the United States. Pharmacoecon Open. 2021;5(4):625\u201333.","journal-title":"Pharmacoecon Open"},{"key":"996_CR25","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.vhri.2018.06.007","volume":"17","author":"MDC Rodriguez-Zepeda","year":"2018","unstructured":"Rodriguez-Zepeda MDC, Gonzalez L, Bravo A, et al. Cost-effectiveness of rFVIIa versus pd-aPCC in the management of mild to moderate bleeds in pediatric patients with hemophilia A with inhibitors in Mexico. Value Health Reg Issues. 2018;17:164\u201373.","journal-title":"Value Health Reg Issues"},{"key":"996_CR26","doi-asserted-by":"publisher","first-page":"207","DOI":"10.2147\/CEOR.S25909","volume":"3","author":"HR Rasekh","year":"2011","unstructured":"Rasekh HR, Imani A, Karimi M, et al. Cost-utility analysis of immune tolerance induction therapy versus on-demand treatment with recombinant factor VII for hemophilia A with high titer inhibitors in Iran. Clinicoecon Outcomes Res. 2011;3:207\u201312.","journal-title":"Clinicoecon Outcomes Res."},{"key":"996_CR27","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2147\/CEOR.S16670","volume":"3","author":"GL Colombo","year":"2011","unstructured":"Colombo GL, Matteo SD, Mancuso ME, et al. Cost-utility analysis of prophylaxis versus treatment on demand in severe hemophilia A. Clinicoecon Outcomes Res. 2011;3:55\u201361.","journal-title":"Clinicoecon Outcomes Res."},{"issue":"9","key":"996_CR28","first-page":"1109","volume":"26","author":"Z-Y Zhou","year":"2020","unstructured":"Zhou Z-Y, Raimundo K, Patel AM, et al. Model of short- and long-term outcomes of emicizumab prophylaxis treatment for persons with Hemophilia A. J Manag Care Spec Pharm. 2020;26(9):1109\u201320.","journal-title":"J Manag Care Spec Pharm"},{"issue":"4","key":"996_CR29","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1111\/j.1365-2516.2009.02019.x","volume":"15","author":"AH Miners","year":"2009","unstructured":"Miners A. Revisiting the cost-effectiveness of primary prophylaxis with clotting factor for the treatment of severe haemophilia A. Haemophilia. 2009;15(4):881\u20137.","journal-title":"Haemophilia"},{"key":"996_CR30","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3111\/200205051064","volume":"5","author":"IAO Odeyemi","year":"2008","unstructured":"Odeyemi I, Guest J. Modelling the economic impact of recombinant activated factor VII and activated prothrombin complex concentrate in the treatment of a mild to moderate bleed in adults with inhibitors to clotting factors VIII and IX at a comprehensive care center in the UK. J Med Econ. 2008;5:51\u201364.","journal-title":"J Med Econ"},{"issue":"11","key":"996_CR31","doi-asserted-by":"publisher","first-page":"759","DOI":"10.2165\/00019053-200220110-00005","volume":"20","author":"AH Miners","year":"2002","unstructured":"Miners AH, Sabin CA, Tolley KH, et al. Cost-utility analysis of primary prophylaxis versus treatment on-demand for individuals with severe haemophilia. Phamacoeconomics. 2002;20(11):759\u201374.","journal-title":"Phamacoeconomics."},{"issue":"7","key":"996_CR32","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1097\/01.mbc.0000178830.39526.ff","volume":"16","author":"B Lippert","year":"2005","unstructured":"Lippert B, Berger K, Berntorp E, et al. Cost effectiveness of haemophilia treatment a cross-national assessment. Blood Coagul Fibrinolysis. 2005;16(7):477\u201385.","journal-title":"Blood Coagul Fibrinolysis"},{"key":"996_CR33","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3111\/200205119133","volume":"5","author":"IAO Odeyemi","year":"2008","unstructured":"Odeyemi I, Guest J. Modelling the economic impact of recombinant activated factor VII compared to activated prothrombin complex concentrate in the home treatment of a mild to moderate bleed in adults with inhibitors to clotting factors VIII and IX in the UK. J Med Econ. 2008;5:119\u201333.","journal-title":"J Med Econ"},{"issue":"9","key":"996_CR34","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1016\/j.clinthera.2021.07.004","volume":"43","author":"G Liu","year":"2021","unstructured":"Liu G, Xin Q, Chen Z, et al. Cost-effectiveness analysis of prophylaxis versus on-demand treatment for children with hemophilia B without inhibitors in China. Clin Ther. 2021;43(9):1536\u201346.","journal-title":"Clin Ther"},{"issue":"1","key":"996_CR35","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1111\/hae.14143","volume":"27","author":"H Lee","year":"2021","unstructured":"Lee H, Cho H, Han JW, et al. Cost-utility analysis of emicizumab prophylaxis in haemophilia A patients with factor VIII inhibitors in Korea. Haemophilia. 2021;27(1):e12-21.","journal-title":"Haemophilia"},{"issue":"2","key":"996_CR36","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1055\/s-0039-3401822","volume":"120","author":"PA Cortesi","year":"2020","unstructured":"Cortesi PA, Castaman G, Trifiro G, et al. Cost-effectiveness and budget impact of emicizumab prophylaxis in haemophilia A patients with inhibitors. Thromb Haemost. 2020;120(2):216\u201328.","journal-title":"Thromb Haemost"},{"issue":"3","key":"996_CR37","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1111\/hae.13185","volume":"23","author":"A Coppola","year":"2017","unstructured":"Coppola A, D\u2019Ausilio A, Aiello A, et al. Cost-effectiveness analysis of late prophylaxis vs. on-demand treatment for severe haemophilia A in Italy. Haemophilia. 2017;23(3):422\u20139.","journal-title":"Haemophilia"},{"issue":"1","key":"996_CR38","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1111\/hae.14129","volume":"27","author":"B Polack","year":"2021","unstructured":"Polack B, Trossaert M, Cousin M, et al. Cost-effectiveness of emicizumab vs bypassing agents in the prevention of bleeding episodes in haemophilia A patients with anti-FVIII inhibitors in France. Haemophilia. 2021;27(1):e1-11.","journal-title":"Haemophilia"},{"issue":"1","key":"996_CR39","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1080\/13696998.2021.1891088","volume":"24","author":"N Li","year":"2021","unstructured":"Li N, Sawyer EK, Maruszczyk K, et al. Adult lifetime cost of hemophilia B management in the US: payer and societal perspectives from a decision analytic model. J Med Econ. 2021;24(1):363\u201372.","journal-title":"J Med Econ"},{"key":"996_CR40","unstructured":"Rind D, Agboola F, Kumar V, et al. Emicizumab for hemophilia A: effectiveness and value final evidence report. 2018;1-162."},{"issue":"40","key":"996_CR41","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000027303","volume":"100","author":"P Saiyarsarai","year":"2021","unstructured":"Saiyarsarai P, Derakhshan AR, Khedmati J, et al. A comparison between on-demand usage of rFVIIa vs prophylaxis use of emicizumab in high titer inhibitory hemophilia A patients in Iran: a cost-utility analysis. Medicine (Baltimore). 2021;100(40):e27303.","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"996_CR42","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1111\/hae.14921","volume":"30","author":"T Seth","year":"2024","unstructured":"Seth T, John MJ, Chakrabarti P, et al. Cost-effectiveness analysis of emicizumab prophylaxis in patients with haemophilia A in India. Haemophilia. 2024;30(2):426\u201336.","journal-title":"Haemophilia"},{"issue":"4","key":"996_CR43","doi-asserted-by":"publisher","first-page":"e228","DOI":"10.1111\/hae.12121","volume":"19","author":"A Farrugia","year":"2013","unstructured":"Farrugia A, Cassar J, Kimber MC, et al. Treatment for life for severe haemophilia A: a cost-utility model for prophylaxis vs. on-demand treatment. Haemophilia. 2013;19(4):e228\u201338.","journal-title":"Haemophilia"},{"issue":"3","key":"996_CR44","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/ejh.13901","volume":"110","author":"N Kragh","year":"2023","unstructured":"Kragh N, Tytula A, Pochopien M, et al. Cost-effectiveness of recombinant factor VIII Fc versus emicizumab for prophylaxis in adults and adolescents with haemophilia A without inhibitors in the UK. Eur J Haematol. 2023;110(3):262\u201370.","journal-title":"Eur J Haematol"},{"issue":"14","key":"996_CR45","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1182\/bloodadvances.2018021345","volume":"2","author":"N Machin","year":"2018","unstructured":"Machin N, Ragni MV, Smith KJ. Gene therapy in hemophilia A: a cost-effectiveness analysis. Blood Adv. 2018;2(14):1792\u20138.","journal-title":"Blood Adv"},{"key":"996_CR46","unstructured":"Rind DM, Agboola F, Herron-Smith S, et al. Valoctocogene roxaparvovec and emicizumab for hemophilia A: effectiveness and value. 2020;1-188."},{"issue":"18","key":"996_CR47","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1182\/blood.2021010864","volume":"138","author":"N Bolous","year":"2021","unstructured":"Bolous N, Chen Y, Wang H, et al. The cost-effectiveness of gene therapy for severe hemophilia B: a microsimulation study from the United States perspective. Blood. 2021;138(18):1677\u201390.","journal-title":"Blood"},{"issue":"3","key":"996_CR48","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s41669-024-00480-z","volume":"8","author":"N Meier","year":"2024","unstructured":"Meier N, Fuchs H, Galactionova K, et al. Cost-effectiveness analysis of etranacogene dezaparvovec versus extended half-life prophylaxis for moderate-to-severe haemophilia B in Germany. Pharmacoeconomics. 2024;8(3):373\u201387.","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"996_CR49","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1111\/hae.14723","volume":"29","author":"JK Yu","year":"2023","unstructured":"Yu JK, Wong WWL, Keepanasseril A, et al. Cost-utility analysis of emicizumab for the treatment of severe hemophilia A patients in Canada. Haemophilia. 2023;29(2):488\u201397.","journal-title":"Haemophilia"},{"issue":"12","key":"996_CR50","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1080\/13696998.2019.1669614","volume":"22","author":"AM Patel","year":"2019","unstructured":"Patel AM, Corman SL, Chaplin S, et al. Economic impact model of delayed inhibitor development in patients with hemophilia A receiving emicizumab for the prevention of bleeding events. J Med Econ. 2019;22(12):1328\u201337.","journal-title":"J Med Econ"},{"key":"996_CR51","unstructured":"CADTH. Drug reimbursement review pharmacoeconomic report emicizumab (hemlibra). 2021;1-39."},{"issue":"3","key":"996_CR52","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/hae.12621","volume":"21","author":"SR Earnshaw","year":"2015","unstructured":"Earnshaw SR, Graham CN, McDade CL, et al. Factor VIII alloantibody inhibitors: cost analysis of immune tolerance induction vs. prophylaxis and on-demand with bypass treatment. Haemophilia. 2015;21(3):310\u20139.","journal-title":"Haemophilia"},{"issue":"1","key":"996_CR53","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s40199-020-00347-8","volume":"28","author":"F Lotfi","year":"2020","unstructured":"Lotfi F, Talebianpour H, Keshavarz K, et al. Cost-utility analysis of factor VIII diet therapies prepared using blood plasma vs. recombinant technique for patients with hemophilia A. Daru. 2020;28(1):287\u201393.","journal-title":"Daru"},{"issue":"4","key":"996_CR54","first-page":"290","volume":"70","author":"G Salinas-Escudero","year":"2013","unstructured":"Salinas-Escudero G, Galindo-Suarez RM, Rely K. Cost-effectiveness analysis of prophylaxis vs. on demand approach in the management in children with hemophilia A in Mexico. Bol Med Hosp Infant Mex. 2013;70(4):290\u20137.","journal-title":"Bol Med Hosp Infant Mex"},{"issue":"5","key":"996_CR55","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1017\/S0266462316000544","volume":"32","author":"HEC Jaramillo","year":"2016","unstructured":"Jaramillo HEC, Viscaya MM, Mejia AE. Cost-utility analysis of primary prophylaxis, compared with on-demand treatment, for patients with severe hemophilia type A in Colombia. Int J Technol Assess Health Care. 2016;32(5):337\u201347.","journal-title":"Int J Technol Assess Health Care"},{"issue":"1","key":"996_CR56","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1080\/16078454.2021.1885123","volume":"26","author":"Z Zahedi","year":"2021","unstructured":"Zahedi Z, Karimi M, Keshavarz K, et al. A cost-effectiveness analysis of the prophylaxis versus on-demand regimens in severe hemophilia A patients under 12 years old in southern Iran. Hematology. 2021;26(1):240\u20138.","journal-title":"Hematology"},{"issue":"1","key":"996_CR57","doi-asserted-by":"publisher","first-page":"2277497","DOI":"10.1080\/16078454.2023.2277497","volume":"28","author":"T Seth","year":"2023","unstructured":"Seth T, Garg K, Mandal PK, et al. Cost-effectiveness analysis of low-dose prophylaxis versus on-demand treatment for moderate-to-severe hemophilia A in India. Hematology. 2023;28(1):2277497.","journal-title":"Hematology"},{"issue":"4","key":"996_CR58","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1080\/13696998.2017.1405816","volume":"21","author":"N Henry","year":"2018","unstructured":"Henry N, Jovanovic J, Schlueter M, et al. Cost-utility analysis of life-long prophylaxis with recombinant factor VIIIFc vs recombinant factor VIII for the management of severe hemophilia A in Sweden. J Med Econ. 2018;21(4):318\u201325.","journal-title":"J Med Econ"},{"issue":"1","key":"996_CR59","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s41669-019-0158-8","volume":"4","author":"A Bullement","year":"2020","unstructured":"Bullement A, McMordie ST, Hatswell AJ, et al. Cost-effectiveness analysis of recombinant factor VIII Fc-fusion protein (rFVIIIFc) for the treatment of severe hemophilia A in Italy. Pharmacoecon Open. 2020;4(1):133\u201342.","journal-title":"Pharmacoecon Open."},{"issue":"1","key":"996_CR60","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/s12874-022-01659-w","volume":"22","author":"R Chen","year":"2022","unstructured":"Chen R, Gultyaev D, Lister J, et al. Pharmacokinetic parameter driven outcomes model predicts a reduction in bleeding events associated with BAY 81\u20138973 versus antihemophilic factor (recombinant) plasma\/albumin-free method in a Chinese healthcare setting. BMC Med Res Methodol. 2022;22(1):215.","journal-title":"BMC Med Res Methodol"},{"issue":"4","key":"996_CR61","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1111\/j.1365-2516.2008.01664.x","volume":"14","author":"N Risebrough","year":"2008","unstructured":"Risebrough N, Oh P, Blanchette V, et al. Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A. Haemophilia. 2008;14(4):743\u201352.","journal-title":"Haemophilia"},{"issue":"6","key":"996_CR62","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1097\/MBC.0000000000000610","volume":"28","author":"S Iannazzo","year":"2017","unstructured":"Iannazzo S, Cortesi PA, Crea R, et al. Cost-effectiveness analysis of pharmacokinetic-driven prophylaxis vs. standard prophylaxis in patients with severe haemophilia A. Blood Coagul Fibrinolysis. 2017;28(6):425\u201330.","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"8","key":"996_CR63","doi-asserted-by":"publisher","first-page":"3777","DOI":"10.1007\/s12325-022-02220-3","volume":"39","author":"C Gu","year":"2022","unstructured":"Gu C, Huang H, Han y. Cost-effectiveness analysis of pharmacokinetic-guided prophylaxis versus standard prophylaxis in adults with severe hemophilia A in China. Adv Ther. 2022;39(8):3777\u201388.","journal-title":"Adv Ther"},{"key":"996_CR64","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/S0022-3476(96)70076-8","volume":"129","author":"P Smith","year":"1996","unstructured":"Smith P, Teutsch SM, Shaffer PA, et al. Episodic versus prophylactic infusions for hemophilia A a cost-effectiveness analysis. J Pediatr. 1996;129:424\u201331.","journal-title":"J Pediatr"},{"issue":"6","key":"996_CR65","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.30264","volume":"70","author":"T Zhou","year":"2023","unstructured":"Zhou T, Wang S, Zhang Y, et al. Cost-effectiveness analysis of recombinant factor IX Fc fusion protein compared with recombinant factor IX for the treatment of moderate-severe to severe hemophilia B in China. Pediatr Blood Cancer. 2023;70(6):e30264.","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"996_CR66","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1007\/s12325-024-02841-w","volume":"41","author":"M Pochopien","year":"2024","unstructured":"Pochopien M, Tytula A, Toumi M, et al. Cost-effectiveness of recombinant factor IX Fc prophylaxis and recombinant factor IX on-demand treatment in patients with haemophilia B without inhibitors. Adv Ther. 2024;41(6):2307\u201323.","journal-title":"Adv Ther"},{"issue":"6","key":"996_CR67","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1111\/hae.12199","volume":"19","author":"V Jimenez-Yuste","year":"2013","unstructured":"Jimenez-Yuste V, Nunez R, Romero JA, et al. Cost-effectiveness of recombinant activated factor VII vs. plasma-derived activated prothrombin complex concentrate in the treatment of mild-to-moderate bleeding episodes in patients with severe haemophilia A and inhibitors in Spain. Haemophilia. 2013;19(6):841\u20136.","journal-title":"Haemophilia"},{"issue":"2","key":"996_CR68","first-page":"669","volume":"15","author":"M Golestani","year":"2016","unstructured":"Golestani M, Eshghi P, Rasekh HR, et al. Cost-effectiveness analysis of biogeneric recombinant activated factor VII (AryoSeven TM) and activated prothrombin complex concentrates (FEIBA TM) to treat hemophilia A patients with inhibitors in Iran. Iran J Pharm Res. 2016;15(2):669\u201377.","journal-title":"Iran J Pharm Res."},{"issue":"5","key":"996_CR69","doi-asserted-by":"publisher","first-page":"e394","DOI":"10.1111\/hae.13294","volume":"23","author":"G Kenet","year":"2017","unstructured":"Kenet G, Oladapo A, Epstein JD, et al. Estimating the potential cost of a high dose immune tolerance induction (ITI) therapy relative to the cost of a combined therapy of a low dose ITI therapy with bypassing agent prophylaxis. Haemophilia. 2017;23(5):e394-402.","journal-title":"Haemophilia"},{"key":"996_CR70","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.vhri.2022.10.007","volume":"34","author":"RM Camelo","year":"2023","unstructured":"Camelo RM, Barbosa MM, Araujo MS, et al. Economic evaluation of immune tolerance induction in children with severe hemophilia A and high-responding inhibitors: a cost-effectiveness analysis of prophylaxis with emicizumab. Value Health Reg Issues. 2023;34:31\u20139.","journal-title":"Value Health Reg Issues"},{"issue":"3","key":"996_CR71","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1055\/s-0033-1334929","volume":"225","author":"K Berger","year":"2013","unstructured":"Berger K, Schopohl D, Eheberg D, et al. Treatment of children with severe haemophilia A and inhibitors: a health economic evaluation for Germany. Klin Padiatr. 2013;225(3):152\u20138.","journal-title":"Klin Padiatr"},{"issue":"2","key":"996_CR72","doi-asserted-by":"publisher","DOI":"10.5867\/medwave.2022.02.002118","volume":"22","author":"R Bitran","year":"2022","unstructured":"Bitran R, Pena C, Arpon P, et al. Cost-effectiveness study of prophylaxis with emicizumab versus bypassing agents in patients with severe hemophilia A in Peru. Medwave. 2022;22(2):e8703.","journal-title":"Medwave."},{"issue":"5","key":"996_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e27089","volume":"10","author":"Y Krishnamoorthy","year":"2024","unstructured":"Krishnamoorthy Y, Govindan D, Kannan N, et al. Budget impact and cost-utility analysis of prophylactic emicizumab versus on-demand bypassing agents for adolescent severe haemophilia A patients with inhibitors in India. Heliyon. 2024;10(5):e27089.","journal-title":"Heliyon."},{"issue":"5","key":"996_CR74","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1182\/blood.V96.5.1698","volume":"96","author":"AB Colowick","year":"2000","unstructured":"Colowick AB, Avorn RJ, Ewenstein B. Immune tolerance induction in hemophilia patients with inhibitors costly can be cheaper. Blood. 2000;96(5):1698\u2013702.","journal-title":"Blood"},{"key":"996_CR75","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1046\/j.1365-2516.2003.00783.x","volume":"9","author":"C Knight","year":"2003","unstructured":"Knight C, Paisley S, Wight J, et al. Economic modelling of different treatment strategies for haemophilia A with high-responding inhibitors. Haemophilia. 2003;9:521\u201340.","journal-title":"Haemophilia"},{"key":"996_CR76","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/j.jval.2012.05.005","volume":"15","author":"EJ Neufeld","year":"2012","unstructured":"Neufeld EJ, Recht M, Sabio H, et al. Effect of acute bleeding on daily quality of life assessments in patients with congenital hemophilia with inhibitors and their families: observations from the dosing observational study in hemophilia. Value Health. 2012;15:916\u201325.","journal-title":"Value Health"},{"issue":"1","key":"996_CR77","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12955-018-0908-9","volume":"16","author":"J O'Hara","year":"2018","unstructured":"O\u2019Hara J, Walsh S, Camp C, et al. The impact of severe haemophilia and the presence of target joints on health-related quality-of-life. Health Qual Life Outcomes. 2018;16(1):84.","journal-title":"Health Qual Life Outcomes"},{"key":"996_CR78","doi-asserted-by":"publisher","first-page":"A593","DOI":"10.1016\/j.jval.2016.09.1420","volume":"19","author":"G Mazza","year":"2016","unstructured":"Mazza G, O\u2019Hara J, Carroll L, et al. The impact of haemophilia complications on health-related quality of life for adults with severe haemophilia. Value Health. 2016;19:A593\u2013A593. https:\/\/doi.org\/10.1016\/j.jval.2016.09.1420.","journal-title":"Value Health"},{"issue":"5","key":"996_CR79","doi-asserted-by":"publisher","first-page":"e375","DOI":"10.1111\/hae.13019","volume":"22","author":"K Fischer","year":"2016","unstructured":"Fischer K, Lewandowski D, Janssen MP. Modelling lifelong effects of different prophylactic treatment strategies for severe haemophilia A. Haemophilia. 2016;22(5):e375\u201382.","journal-title":"Haemophilia"},{"issue":"3","key":"996_CR80","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1185\/030079908X273048","volume":"24","author":"RD Ballal","year":"2008","unstructured":"Ballal RD, Botteman MF, Foley I, et al. Economic evaluation of major knee surgery with recombinant activated factor VII in hemophilia patients with high titer inhibitors and advanced knee arthropathy: exploratory results via literature-based modeling. Curr Med Res Opin. 2008;24(3):753\u201368.","journal-title":"Curr Med Res Opin"},{"issue":"11","key":"996_CR81","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.2106\/00004623-199311000-00006","volume":"75","author":"A Laupacis","year":"1993","unstructured":"Laupacis A, Bourne R, Rorabeck C, et al. The effect of elective total hip replacement on health-related quality of life. J Bone Jt Surg. 1993;75(11):1619\u201326.","journal-title":"J Bone Jt Surg"},{"issue":"1","key":"996_CR82","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1365-2516.2012.02934.x","volume":"19","author":"D Noone","year":"2013","unstructured":"Noone D, O\u2019Mahony B, Van Dijk JP, et al. A survey of the outcome of prophylaxis, on-demand treatment or combined treatment in 18\u201335-year old men with severe haemophilia in six countries. Haemophilia. 2013;19(1):44\u201350.","journal-title":"Haemophilia"},{"issue":"5","key":"996_CR83","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/j.1524-4733.2010.00700.x","volume":"13","author":"R Ara","year":"2010","unstructured":"Ara R, Brazier JE. Populating an economic model with health state utility values: moving toward better practice. Value Health. 2010;13(5):509\u201318.","journal-title":"Value Health"},{"issue":"9","key":"996_CR84","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1703068","volume":"377","author":"J Oldenburg","year":"2017","unstructured":"Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017;377(9):809\u201318.","journal-title":"N Engl J Med"},{"issue":"6","key":"996_CR85","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1046\/j.1365-2516.1999.00347.x","volume":"5","author":"AH Miners","year":"1999","unstructured":"Miners AH, Sabin A, Tolley KH, et al. Assessing health-related quality-of-life in individuals with haemophilia. Haemophilia. 1999;5(6):378\u201385.","journal-title":"Haemophilia"},{"key":"996_CR86","first-page":"632","volume":"24","author":"T Thorat","year":"2018","unstructured":"Thorat T, Neumann PJ, Chambers JD. Hemophilia burden of disease: a systematic review of the cost-utility literature for hemophilia. J Manag Care Spec Pharm. 2018;24:632\u201342.","journal-title":"J Manag Care Spec Pharm"},{"issue":"12","key":"996_CR87","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1002\/hec.1148","volume":"15","author":"A Brennan","year":"2006","unstructured":"Brennan A, Chick SE, Davies R. A taxonomy of model structures for economic evaluation of health technologies. Health Econ. 2006;15(12):1295\u2013310.","journal-title":"Health Econ"},{"issue":"5","key":"996_CR88","doi-asserted-by":"publisher","first-page":"461","DOI":"10.2165\/00019053-200017050-00005","volume":"17","author":"M Schulper","year":"2000","unstructured":"Schulper M, Fenwick E, Claxton K. Assessing quality in decision analytic cost-effectiveness models. Phamacoeconomics. 2000;17(5):461\u201377.","journal-title":"Phamacoeconomics."},{"key":"996_CR89","doi-asserted-by":"crossref","unstructured":"Briggs A, Scupher M, Claxton K, et al. Decision modelling for health economic evaluation. Oxford University Press; 2006:236.","DOI":"10.1093\/oso\/9780198526629.001.0001"},{"issue":"1","key":"996_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2022.100007","volume":"7","author":"AD Shapiro","year":"2023","unstructured":"Shapiro AD, Hardesty BM, Peyvandi F, et al. Prevalence of selected bleeding and thrombotic events in persons with hemophilia versus the general population: a scoping review. Res Pract Thromb Haemost. 2023;7(1):100007.","journal-title":"Res Pract Thromb Haemost"},{"issue":"11","key":"996_CR91","volume":"11","author":"B Chin","year":"2022","unstructured":"Chin B, Wee I, Syn NLX, et al. Surgery for chronic arthropathy in people with haemophilia. Cochrane Database Syst Rev. 2022;11(11):CD013634.","journal-title":"Cochrane Database Syst Rev"},{"issue":"Suppl. 1","key":"996_CR92","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1111\/j.1538-7836.2007.02503.x","volume":"5","author":"HM Van Den Berg","year":"2007","unstructured":"van den Berg HM, De Groot PH, Fischer K. Phenotypic heterogeneity in severe hemophilia. J Thromb Haemost. 2007;5(Suppl. 1):151\u20136.","journal-title":"J Thromb Haemost"},{"issue":"3","key":"996_CR93","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1002\/rth2.12106","volume":"2","author":"A Iorio","year":"2018","unstructured":"Iorio A, Edginton AN, Blanchette V, et al. Performing and interpreting individual pharmacokinetic profiles in patients with hemophilia A or B: rationale and general considerations. Res Pract Thromb Haemost. 2018;2(3):535\u201348.","journal-title":"Res Pract Thromb Haemost"},{"key":"996_CR94","doi-asserted-by":"crossref","unstructured":"Philips Z, Ginnelly L, Schulper M, et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess. 2004;8(36): 1\u2013158.","DOI":"10.3310\/hta8360"},{"issue":"5","key":"996_CR95","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1177\/0272989X12454941","volume":"32","author":"M Roberts","year":"2012","unstructured":"Roberts M, Russell LB, Paltiel AD, et al. Conceptualizing a model: a report of the ISPOR-SMDM modeling good research practices task force-2. Med Decis Mak. 2012;32(5):678\u201389.","journal-title":"Med Decis Mak"},{"issue":"2","key":"996_CR96","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1111\/hae.12009","volume":"19","author":"AH Miners","year":"2013","unstructured":"Miners AH. Economic evaluations of prophylaxis with clotting factor for people with severe haemophilia: why do the results vary so much? Haemophilia. 2013;19(2):174\u201380.","journal-title":"Haemophilia"},{"issue":"6","key":"996_CR97","first-page":"535","volume":"16","author":"G Benson","year":"2018","unstructured":"Benson G, Auerswald G, Dolan G, et al. Diagnosis and care of patients with mild haemophilia: practical recommendations for clinical management. Blood Transfus. 2018;16(6):535\u201344.","journal-title":"Blood Transfus"},{"key":"996_CR98","unstructured":"EHC. Novel treatments in haemophilia and other bleeding disorders: a periodic EHC Review. European Hemophilia Consortium. 2024;1-52."}],"container-title":["Applied Health Economics and Health Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-025-00996-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40258-025-00996-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-025-00996-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T12:02:05Z","timestamp":1768046525000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40258-025-00996-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,31]]},"references-count":98,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["996"],"URL":"https:\/\/doi.org\/10.1007\/s40258-025-00996-3","relation":{},"ISSN":["1175-5652","1179-1896"],"issn-type":[{"value":"1175-5652","type":"print"},{"value":"1179-1896","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,31]]},"assertion":[{"value":"18 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The SYMPHONY consortium, which aims to orchestrate personalised treatment in patients with bleeding disorders, is a unique collaboration between patients, healthcare professionals, and translational and fundamental researchers specialised in iBDs, as well as experts from multiple disciplines. It aims to identify the best treatment choice for each individual based on the bleeding phenotype. To achieve this goal, work packages (WPs) have been organised according to three themes, for example Diagnostics (WPs 3&4), Treatment (WPs 5-9) and Fundamental Research (WPs 10-12). This research receives funding from the Netherlands Organization for Scientific Research (NWO) in the framework of the NWA-ORC call grant agreement NWA.1160.18.038. Principal investigator: Prof. M.H. Cnossen. Project manager: Dr. S.H. Reitsma. More information:\u00a0\n                      \n                      . Beneficiaries of the SYMPHONY consortium: Erasmus University Medical Center-Sophia Children\u2019s Hospital, project leadership and coordination; Sanquin Diagnostics; Sanquin Research; Amsterdam University Medical Centers; University Medical Center Groningen; University Medical Center Utrecht; Leiden University Medical Center; Radboud University Medical Center; Netherlands Society of Hemophilia Patients (NVHP); Netherlands Society for Thrombosis and Hemostasis (NVTH); Bayer B.V., CSL Behring B.V., Swedish Orphan Biovitrum (Belgium) BVBA\/SPRL. Additional beneficiaries that are not included in the SYMPHONY consortium funding parallel projects are: Novonordisk (OPTI-CLOT TARGET), Roche (Partitura), Stichting Haemophilia (patient-reported outcomes project).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Marjon H. Cnossen has received investigator-initiated research and travel grants as well as speaker fees over the years from the Netherlands Organization for Scientific Research (NWO) and Netherlands National Research Agenda (NWA), the Netherlands Organization for Health Research and Development (ZonMw), the Dutch Innovatiefonds Zorgverzekeraars, Stichting Haemophilia, Baxter\/Baxalta\/Shire\/ Takeda, Pfizer, Bayer Schering Pharma, CSL Behring, Sobi Biogen, Novo Nordisk, Novartis, Roche and Nordic Pharma, and for serving as a steering board member for Roche, Bayer and Novartis. All grants and fees go to the Erasmus MC as an institution. She is a coordinator of Erasmus MC as a Health Care Provider within the European Reference Network for rare hematological diseases EuroBloodNet and a (co)leader of the local Erasmus MC Expert Centers for Rare Bleeding Disorders and Sickle Cell and Thalassemia Comprehensive Care Center. Renske M.T. Ten Ham is the author of one of the studies included in this review. Diaz M. Prameyllawati and Hester F. Lingsma have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The complete search strategy for each database is detailed in Table 1 of the ESM. The data extraction table for each population type is included within this article.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Concept and design: DMP, HFL, MHC, RMTTH; reviewer: DMP, RMTTH; data extraction: DMP; analysis and interpretation of data: DMP, RMTTH; drafting of the manuscript: DMP, HFL, MHC, RMTTH; critical revision of paper for important intellectual content: HFL, MHC, RMTTH; obtaining funding: MHC; administrative, technical or logistic support: HF, MHC, RMTTH; supervision: HFL, MHC, RMTTH.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}